[{"id":"d1947b42-42fd-4782-93fd-228a17b831b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05372367","created_at":"2022-05-12T14:59:38.525Z","updated_at":"2025-02-25T16:39:01.449Z","phase":"Phase 1","brief_title":"A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor","source_id_and_acronym":"NCT05372367","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • itraconazole • rifampicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 06/13/2025","study_completion_date":" 06/13/2025","last_update_posted":"2025-02-07"},{"id":"90a38f06-27ea-4209-9048-d2904418d6ca","acronym":"PROFILE 1001","url":"https://clinicaltrials.gov/study/NCT00585195","created_at":"2021-01-17T17:10:29.976Z","updated_at":"2024-07-02T16:35:56.286Z","phase":"Phase 1","brief_title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","source_id_and_acronym":"NCT00585195 - PROFILE 1001","lead_sponsor":"Pfizer","biomarkers":" ALK • MET • CYP3A4","pipe":" | ","alterations":" ALK negative","tags":["ALK • MET • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • itraconazole • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 596","initiation":"Initiation: 04/19/2006","start_date":" 04/19/2006","primary_txt":" Primary completion: 07/30/2020","primary_completion_date":" 07/30/2020","study_txt":" Completion: 01/19/2022","study_completion_date":" 01/19/2022","last_update_posted":"2023-02-07"},{"id":"ba7b0b88-3ab3-421d-9de0-1c64d1ab0853","acronym":"","url":"https://clinicaltrials.gov/study/NCT00207090","created_at":"2021-01-18T00:42:15.519Z","updated_at":"2024-07-02T16:36:39.328Z","phase":"Phase 1","brief_title":"Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer","source_id_and_acronym":"NCT00207090","lead_sponsor":"R-Pharm","biomarkers":" CYP3A4","pipe":"","alterations":" ","tags":["CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ixempra (ixabepilone) • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 11/01/2008","primary_completion_date":" 11/01/2008","study_txt":" Completion: 11/01/2008","study_completion_date":" 11/01/2008","last_update_posted":"2020-11-02"},{"id":"8ef02209-9fbb-4f43-9d72-74aec4dc298f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04118842","created_at":"2021-01-18T20:07:50.696Z","updated_at":"2024-07-02T16:36:46.689Z","phase":"Phase 1","brief_title":"A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin","source_id_and_acronym":"NCT04118842","lead_sponsor":"AstraZeneca","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib) • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/17/2019","start_date":" 10/17/2019","primary_txt":" Primary completion: 02/26/2020","primary_completion_date":" 02/26/2020","study_txt":" Completion: 02/26/2020","study_completion_date":" 02/26/2020","last_update_posted":"2020-04-03"},{"id":"0bce315d-d14f-4147-a8b1-f9cc4f346fd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02608034","created_at":"2021-01-18T12:40:05.887Z","updated_at":"2024-07-02T16:36:50.102Z","phase":"Phase 1","brief_title":"A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State","source_id_and_acronym":"NCT02608034","lead_sponsor":"Genentech, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • itraconazole • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 05/26/2016","start_date":" 05/26/2016","primary_txt":" Primary completion: 09/10/2018","primary_completion_date":" 09/10/2018","study_txt":" Completion: 09/10/2018","study_completion_date":" 09/10/2018","last_update_posted":"2020-02-12"},{"id":"01bcc80b-5d58-47f6-9247-0c68750a5cf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324323","created_at":"2021-01-18T05:23:33.157Z","updated_at":"2024-07-02T16:36:53.238Z","phase":"Phase 1","brief_title":"Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer","source_id_and_acronym":"NCT01324323","lead_sponsor":"Celgene","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 03/01/2012","study_completion_date":" 03/01/2012","last_update_posted":"2019-11-25"},{"id":"2d66b570-8423-4299-8a62-9d22e9c4f4f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01765543","created_at":"2021-01-18T07:46:01.926Z","updated_at":"2024-07-02T16:37:27.054Z","phase":"Phase 1","brief_title":"A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)","source_id_and_acronym":"NCT01765543","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2016-12-15"}]